Skip to main content

Technical View: Nifty forms Shooting Star pattern, sideways trade to continue

As trade seems to be sideways, Mazhar Mohammad of Chartviewindia.in advises traders to remain neutral on the index.

The Nifty50 traded higher for the third consecutive day but remained in consolidative mode on October 20, with profit-booking at higher levels in the last couple of hours of trade forcing the index off the day's high.

After opening lower at 11,861, the Nifty immediately gained strength to hit an intraday high of 11,949.25. It saw some profit-booking at higher levels in the last hours and ended the day at 11,896.80, up 23.80 points.

The index failed to hold on to 11,900-mark and formed a small-bodied bullish candle that resembled a Shooting Star kind of pattern on the daily charts.

A 'Shooting Star' pattern is formed when the index comes under selling pressure as traders start booking profits at higher levels. The pattern is usually formed in an uptrend and is treated as a reversal pattern, which requires confirmation that the trend will get reversed in the near future.



A strong uptrend is unlikely in the coming days unless the index closes above 12,025, experts said.

As trade seems to be sideways, traders should remain neutral on the index, Mazhar Mohammad, Chief Strategist – Technical Research & Trading Advisory at Chartviewindia.in told Moneycontrol.

"Despite positive price action for the day, Nifty50 appears to have witnessed intraday profit booking from the exact resistance point of 11,950 levels, which depicted a Shooting Star kind of formation with long upper shadow but with relatively lower candle body," Mohammad said.

Hence, he feels in the next trading session if the index slips below 11,837 then it can attract intraday selling pressure and can make an attempt to bridge the bullish gap present between 11,820 – 11,789 levels registered on October 19.

Contrary to this if the bulls manage to defend 11,837, then the trade for the next session can be sideways with positive bias with the likelihood of retesting the recent corrective swing high of 12,025 levels, according to him.

However, the current rally from the lows of 11,661 is still looking like a counter-trend move and hence outright bullish opinion shall not be formed unless the Nifty registers a strong close above 12,025 levels, he said.

India VIX moved up by 3.99 percent from 21.82 to 22.69 levels. Chandan Taparia of Motilal Oswal feels VIX needs to cool down below 19 zones for market stability but volatility could spike ahead of US elections.

On the options front, maximum Put open interest was at 10,500 followed by 11,000 strike, while maximum Call open interest was at 12,500 followed by 12,000 strike. Call writing was seen at 12,000 then 12,500 strike while Put writing was seen at 11,500 then 11,600 strike.

The abovementioned option data indicated an immediate trading range for the Nifty at 11,750 to 12,000 levels.

The Bank Nifty opened negative at 24,117.35 but managed to hold 24,000- mark and headed higher to hit an intraday high of 24,410.90.

The index has been making higher lows on the weekly scale and holding well above the previous hurdle of 24,000-24,200. It closed 45.05 points higher at 24,311.80 and formed a bullish candle on the daily scale.

"The index has been making higher highs-higher lows from the last three trading sessions. Now it has to hold above 24,000 to witness an upmove towards 24,750 then 25,000 while on the downside support exists at 23,750 then 23,500," Chandan Taparia, Vice President | Analyst-Derivatives at Motilal Oswal Financial Services said.

Positive setup was seen in Asian Paints, Dabur, HCL Technologies, Zee Entertainment, Bharti Infratel, Tech Mahindra, HDFC Bank, L&T, JSW Steel, Wipro and Infosys while weakness was seen in UPL, Reliance Industries, Hindalco, Kotak Mahindra Bank and ICICI Bank, he added.

Comments

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...